Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $43.6 million.

  • ImmunityBio's Accumulated Expenses rose 1.38% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 1.38%. This contributed to the annual value of $40.6 million for FY2024, which is 498.27% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Accumulated Expenses is $43.6 million, which was up 1.38% from $35.7 million recorded in Q2 2025.
  • ImmunityBio's 5-year Accumulated Expenses high stood at $64.9 million for Q3 2023, and its period low was $27.9 million during Q1 2025.
  • In the last 5 years, ImmunityBio's Accumulated Expenses had a median value of $43.6 million in 2024 and averaged $45.7 million.
  • As far as peak fluctuations go, ImmunityBio's Accumulated Expenses skyrocketed by 60072.77% in 2021, and later plummeted by 4329.99% in 2024.
  • Quarter analysis of 5 years shows ImmunityBio's Accumulated Expenses stood at $51.4 million in 2021, then decreased by 18.61% to $41.8 million in 2022, then rose by 2.11% to $42.7 million in 2023, then fell by 4.98% to $40.6 million in 2024, then grew by 7.45% to $43.6 million in 2025.
  • Its Accumulated Expenses stands at $43.6 million for Q3 2025, versus $35.7 million for Q2 2025 and $27.9 million for Q1 2025.